| 000 | 01801 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517043350.0 | ||
| 264 | 0 | _c20161017 | |
| 008 | 201610s 0 0 eng d | ||
| 022 | _a1029-2330 | ||
| 024 | 7 |
_a10.3109/1061186X.2015.1055568 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJiang, Linlin | |
| 245 | 0 | 0 |
_aA novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity. _h[electronic resource] |
| 260 |
_bJournal of drug targeting _c2016 |
||
| 300 |
_a47-57 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAminoglycosides _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAntigens, CD19 _ximmunology |
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aCell Survival |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Carriers |
| 650 | 0 | 4 |
_aEnediynes _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHeterografts |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, B-Cell _xphysiopathology |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadministration & dosage |
| 700 | 1 | _aYang, Ming | |
| 700 | 1 | _aZhang, Xiaoyun | |
| 700 | 1 | _aBao, Shiqi | |
| 700 | 1 | _aMa, Li | |
| 700 | 1 | _aFan, Dongmei | |
| 700 | 1 | _aZhou, Yuan | |
| 700 | 1 | _aXiong, Dongsheng | |
| 700 | 1 | _aZhen, Yongsu | |
| 773 | 0 |
_tJournal of drug targeting _gvol. 24 _gno. 1 _gp. 47-57 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/1061186X.2015.1055568 _zAvailable from publisher's website |
| 999 |
_c25102854 _d25102854 |
||